Artwork

Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

A roadmap to ALS prevention: strategies and priorities

38:29
 
Share
 

Manage episode 367424118 series 9877
Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode, JNNP's new podcast host Dr. Saima Chaudhry (1) speaks with Dr. Michael Benatar (2) about his recently published article, "A roadmap to ALS prevention: strategies and priorities". This explores a new approach to Amyotrophic lateral sclerosis, with an emphasis on earlier treatment before significant damage has occurred. This is important due to the limited capacity of the central nervous system to repair itself. The researchers involved sought to understand contributing factors for ALS risk, and to identify high-risk groups for further study.

Note: The genetic therapy referred to as Tofersen, under review at the time of recording, has been approved by the FDA: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene

You can read the paper at the following link: https://jnnp.bmj.com/content/94/5/399

(1) Warren Alpert Medical School, Brown University, Rhode Island, USA

(2) Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA

Please subscribe to the show on Apple Podcasts, Spotify or find it on your platform of choice. Your feedback and reviews are very appreciated.

Follow JNNP on twitter: @JNNP_BMJ

  continue reading

207 episodes

Artwork
iconShare
 
Manage episode 367424118 series 9877
Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode, JNNP's new podcast host Dr. Saima Chaudhry (1) speaks with Dr. Michael Benatar (2) about his recently published article, "A roadmap to ALS prevention: strategies and priorities". This explores a new approach to Amyotrophic lateral sclerosis, with an emphasis on earlier treatment before significant damage has occurred. This is important due to the limited capacity of the central nervous system to repair itself. The researchers involved sought to understand contributing factors for ALS risk, and to identify high-risk groups for further study.

Note: The genetic therapy referred to as Tofersen, under review at the time of recording, has been approved by the FDA: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene

You can read the paper at the following link: https://jnnp.bmj.com/content/94/5/399

(1) Warren Alpert Medical School, Brown University, Rhode Island, USA

(2) Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA

Please subscribe to the show on Apple Podcasts, Spotify or find it on your platform of choice. Your feedback and reviews are very appreciated.

Follow JNNP on twitter: @JNNP_BMJ

  continue reading

207 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play